UniQure and REGENXBIO are both dealing with FDA setbacks for their respective gene therapies, as regulatory experts question the FDA’s decision-making processes; CBER director Vinay Prasad is under ...

RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...

Learn the distinctions between simple and stratified random sampling. Understand how researchers use these methods to accurately represent data populations.

Good afternoon, and thank you for joining us for Quantum Computing, Inc.’s fourth quarter and full year 2025 earnings call.